jack andraka

3 Posts | Page(s): 1 

jack andraka

by sjbrcaconc on Tue Dec 04, 2012 05:03 AM

Quote | Reply

all pancreatic cancer patients research this boy!!!!jack andraka he is a 15 yr old wiz kid who will no dought be saving lives one day soon   too bad he didnt come along sooner as my husband passed away this july of pancreatic cancer in 6 short months after his diagnosis...this boys uncle died from pancreatic cancer also hense his interests   please research him go to you tube to the intel science awards   hope  the best to you all...be strong

RE: jack andraka

by maxxschiken on Tue Dec 04, 2012 02:45 PM

Quote | Reply

He's a genius!  Saw him on a few different programs on television and on the internet.  It's just sad with all the bureaucracy who knows how long it will take before his research is put into play.  Thousands will perish from cancer before they even begin to develop a protocol for humans.  

On a lighter note though here is something you all may find interesting. My wife has been taking this drug since 2006, six years prior to her diagnosis of stage 4 pc back in July of 2011.  She's alive and in remission today after 10 months of Folfirinox in conjuction with this treatment for her diabetes:

Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines
Posted On: June 19, 2012 – 8:00pm

LAKE TAHOE, Nev. — Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively destroy cancer stem cells, a group of cells that are considered to be responsible for tumor initiation and, because they are resistant to standard chemotherapies, tumor relapse.

In addition, when metformin was combined with a standard chemotherapy used for pancreatic cancer, the combination treatment was able to efficiently eradicate both cancer stem cells and more differentiated cancer cells, which form the bulk of the tumor, according to data presented by Christopher Heeschen, M.D., Ph.D., at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges conference, held in Lake Tahoe, Nev., from June 18-21, 2012. Heeschen is professor for experimental medicine at the Spanish National Cancer Research Centre in Madrid, Spain.

Most clinical trials of pancreatic cancer conducted during the last 15 years have failed to show marked improvement in median survival, suggesting that the selected approaches were not sufficient for several reasons, according to Heeschen. In recent years, researchers have identified cancer stem cells which, as opposed to the cancer cells that make up the bulk of the tumor, are a small subset of cells that are resistant to conventional therapy.

“Therefore, efficiently targeting these cells will be crucial for achieving higher cure rates in patients with pancreatic cancer,” he said. “Our newly emerging data now indicate that metformin, a widely used and well-tolerated drug for the treatment of diabetes, is capable of efficiently eliminating these cells.”

Specifically, the researchers found that metformin-pretreated cancer stem cells were particularly sensitive to alterations to their metabolism through the activation of AMPK. In fact, metformin treatment resulted in the death of cancer stem cells. In contrast, treatment of more differentiated cancer cells with metformin only arrested the cells’ growth.

“As the cancer stem cells represent the root of pancreatic cancer, their extinction by reprogramming their metabolism with metformin in combination with the stalling of the proliferation of more differentiated cells should result in tumor regression and long-term, progression-free survival,” Heeschen said.

The researchers generated data to support this idea when they treated immunocompromised mice implanted with a diverse set of patient-derived tumors with a combination of metformin and gemcitabine, the standard chemotherapeutic treatment for pancreatic cancer. They found that the treatment resulted in reduced tumor burden and the prevention of relapse as compared with treatment with either drug alone.

“Intriguingly, in all tumors treated with metformin to date, relapse of disease was efficiently prevented and there were no noticeable adverse effects,” Heeschen said.

He believes that testing metformin in pancreatic cancer is ready for clinical trials. The pancreatic research team is currently awaiting results of a study that tested metformin as a maintenance treatment in patients with advanced pancreatic cancer. Although the rationale for this study was based on retrospective data, Heeschen said given these new results he hopes that this treatment strategy would be highly efficacious.

“Pending the results of this study, an important aspect for the future will be to investigate if all patients respond to metformin or whether some patients, due to distinct genetic alterations, may not respond to this metabolic reprogramming,” he said.

RE: jack andraka

by lucky2Bhere on Wed Dec 05, 2012 01:29 AM

Quote | Reply

On Dec 04, 2012 2:45 PM maxxschiken wrote:

He's a genius!  Saw him on a few different programs on television and on the internet.  It's just sad with all the bureaucracy who knows how long it will take before his research is put into play.  Thousands will perish from cancer before they even begin to develop a protocol for humans.  

On a lighter note though here is something you all may find interesting. My wife has been taking this drug since 2006, six years prior to her diagnosis of stage 4 pc back in July of 2011.  She's alive and in remission today after 10 months of Folfirinox in conjuction with this treatment for her diabetes:

Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines
Posted On: June 19, 2012 – 8:00pm

LAKE TAHOE, Nev. — Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively destroy cancer stem cells, a group of cells that are considered to be responsible for tumor initiation and, because they are resistant to standard chemotherapies, tumor relapse.

In addition, when metformin was combined with a standard chemotherapy used for pancreatic cancer, the combination treatment was able to efficiently eradicate both cancer stem cells and more differentiated cancer cells, which form the bulk of the tumor, according to data presented by Christopher Heeschen, M.D., Ph.D., at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges conference, held in Lake Tahoe, Nev., from June 18-21, 2012. Heeschen is professor for experimental medicine at the Spanish National Cancer Research Centre in Madrid, Spain.

Most clinical trials of pancreatic cancer conducted during the last 15 years have failed to show marked improvement in median survival, suggesting that the selected approaches were not sufficient for several reasons, according to Heeschen. In recent years, researchers have identified cancer stem cells which, as opposed to the cancer cells that make up the bulk of the tumor, are a small subset of cells that are resistant to conventional therapy.

“Therefore, efficiently targeting these cells will be crucial for achieving higher cure rates in patients with pancreatic cancer,” he said. “Our newly emerging data now indicate that metformin, a widely used and well-tolerated drug for the treatment of diabetes, is capable of efficiently eliminating these cells.”

Specifically, the researchers found that metformin-pretreated cancer stem cells were particularly sensitive to alterations to their metabolism through the activation of AMPK. In fact, metformin treatment resulted in the death of cancer stem cells. In contrast, treatment of more differentiated cancer cells with metformin only arrested the cells’ growth.

“As the cancer stem cells represent the root of pancreatic cancer, their extinction by reprogramming their metabolism with metformin in combination with the stalling of the proliferation of more differentiated cells should result in tumor regression and long-term, progression-free survival,” Heeschen said.

The researchers generated data to support this idea when they treated immunocompromised mice implanted with a diverse set of patient-derived tumors with a combination of metformin and gemcitabine, the standard chemotherapeutic treatment for pancreatic cancer. They found that the treatment resulted in reduced tumor burden and the prevention of relapse as compared with treatment with either drug alone.

“Intriguingly, in all tumors treated with metformin to date, relapse of disease was efficiently prevented and there were no noticeable adverse effects,” Heeschen said.

He believes that testing metformin in pancreatic cancer is ready for clinical trials. The pancreatic research team is currently awaiting results of a study that tested metformin as a maintenance treatment in patients with advanced pancreatic cancer. Although the rationale for this study was based on retrospective data, Heeschen said given these new results he hopes that this treatment strategy would be highly efficacious.

“Pending the results of this study, an important aspect for the future will be to investigate if all patients respond to metformin or whether some patients, due to distinct genetic alterations, may not respond to this metabolic reprogramming,” he said.

Thanks maxxschiken! I copied this to give to my oncologist when I see him end of Jan 2013.

God Bless You & All of the wonderful patients, caregivers & families on this site! You are all an inspiration to others, the words of Hope, Healing, & Heartfelt caring & support is something I am so very grateful! Hugs, Candy

3 Posts | Page(s): 1 
Subscribe to this message board discussion

Latest Messages

View More

CancerCompass Survey

If you were considering traveling for cancer treatment, which headline would you find more interesting?

Get $75 for taking a research survey

We care about your feedback. Let us know how we can improve your CancerCompass experience.